- Home
- SYRE vs ADEA Comparison
SYRE vs ADEA Comparison
Compare SYRE & ADEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SYRE
- ADEA
- Stock Information
- Founded
- SYRE 2013
- ADEA 1990
- Country
- SYRE United States
- ADEA United States
- Employees
- SYRE 60
- ADEA N/A
- Industry
- SYRE Biotechnology: Pharmaceutical Preparations
- ADEA Computer Software: Prepackaged Software
- Sector
- SYRE Health Care
- ADEA Technology
- Exchange
- SYRE Nasdaq
- ADEA Nasdaq
- Market Cap
- SYRE 1.3B
- ADEA 1.5B
- IPO Year
- SYRE 2016
- ADEA N/A
- Fundamental
- Price
- SYRE $21.29
- ADEA $17.23
- Analyst Decision
- SYRE Strong Buy
- ADEA Strong Buy
- Analyst Count
- SYRE 8
- ADEA 3
- Target Price
- SYRE $51.50
- ADEA $18.33
- AVG Volume (30 Days)
- SYRE 550.7K
- ADEA 565.8K
- Earning Date
- SYRE 03-03-2025
- ADEA 02-18-2025
- Dividend Yield
- SYRE N/A
- ADEA 1.53%
- EPS Growth
- SYRE N/A
- ADEA N/A
- EPS
- SYRE N/A
- ADEA 0.57
- Revenue
- SYRE N/A
- ADEA $376,024,000.00
- Revenue This Year
- SYRE $168.62
- ADEA N/A
- Revenue Next Year
- SYRE $47.61
- ADEA $10.09
- P/E Ratio
- SYRE N/A
- ADEA $30.04
- Revenue Growth
- SYRE N/A
- ADEA N/A
- 52 Week Low
- SYRE $20.13
- ADEA $9.68
- 52 Week High
- SYRE $47.97
- ADEA $14.75
- Technical
- Relative Strength Index (RSI)
- SYRE 40.66
- ADEA 83.43
- Support Level
- SYRE $21.61
- ADEA $13.20
- Resistance Level
- SYRE $23.04
- ADEA $17.46
- Average True Range (ATR)
- SYRE 1.43
- ADEA 0.57
- MACD
- SYRE -0.03
- ADEA 0.51
- Stochastic Oscillator
- SYRE 22.03
- ADEA 95.53
About SYRE Spyre Therapeutics Inc.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. A range of pharmaceutical options to address IBD exists, including anti-inflammatory drugs, immunosuppressants, and biologics.
About ADEA Adeia Inc.
Adeia Inc is a consumer and entertainment product/solutions licensing company. Its only operating segment being Intellectual Property Licensing (IP). In the IP segment, it primarily license innovations to leading companies in the broader entertainment industry, and those developing new technologies that will help drive this industry forward. It includes Pay-TV, Consumer Electronics, Connected Car, and Media Platform.